The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1432
TNF Inhibitors for Crohn's Disease: When, Which, and for How Long
The full article is available to subscribers Subscriber Login   

Three tumor necrosis factor (TNF) inhibitors – infliximab (Remicade), adalimumab (Humira), and certolizumab pegol (Cimzia) – are approved by the FDA for treatment of moderately to severely active Crohn's disease in adults who have had an inadequate response to conventional therapy. Infliximab is also FDA-approved for the same indication in children ≥6 years old and for treatment of fistulas in adults. All 3 TNF inhibitors have been shown to reduce the signs and symptoms of Crohn's disease in clinical trials.1,2 They have been associated with adverse effects such as tuberculosis, other serious infections, and lymphoma, and they are expensive.1

CLINICAL USE — In addition to being used for treatment of disease that has not responded to other drugs, TNF inhibitors have been effectively used (off-label) as ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: TNF Inhibitors for Crohn's Disease: When, Which, and for How Long
Article code: 1432b
 Electronic, downloadable article - $35
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian